Unum Therapeutics Funding & Investors
Cogent Biosciences, Inc. operates as a biotechnology company. The Company focuses on development and commercialization of solutions to treat cancers, autoimmune conditions, and rare diseases. Cogent Biosciences serves patients worldwide.
unumrx.comTotal Amount Raised: $692,700,032
Unum Therapeutics Funding Rounds
Post Ipo Equity
$150,000,000
Post Ipo Equity
$150,000,000
Post Ipo Equity
$60,000,000
Post Ipo Equity
$104,400,000
Post Ipo Equity Investors
RTW InvestmentsLogos CapitalAlly Bridge GroupFairmount Funds ManagementAcorn BioventuresPerceptive AdvisorsBiotechnology Value FundOrbiMed AdvisorsVenrock Healthcare Capital PartnersAtlas VentureSamsara BioCapitalCommodore CapitalPost Ipo Equity
$50,000,000
Corporate Round
$86,000,000
Debt Financing
$15,000,000
Debt Financing Investors
Square 1 BankSeries B
$65,000,000
Series B Investors
Jennison AssociatesNovo HoldingsSabby ManagementSectoral Asset ManagementWellington ManagementBrace PharmaSanofi VenturesSeagenF-Prime CapitalCowenAtlas VentureNew Leaf Venture PartnersSeries A
$12,300,000
Series A Investors
Eight Roads VenturesSanofi VenturesF-Prime CapitalAtlas Venture
Funding info provided by Diffbot.